Apolipoprotein B is the "bad" apolipoprotein that promotes atherosclerosis.
Apolipoprotein B (ApoB) is the major structural protein found on all atherogenic lipoproteins—including VLDL, IDL, LDL, and lipoprotein(a)—and directly drives atherosclerotic plaque formation, arterial inflammation, and cardiovascular events 1, 2.
Why ApoB is Atherogenic
Each atherogenic lipoprotein particle contains exactly one ApoB molecule, making ApoB concentration a direct measure of the total number of atherogenic particles in circulation 1. This is fundamentally different from measuring cholesterol content alone, which can be misleading.
The mechanism is straightforward: ApoB-containing particles cross the endothelial barrier and become retained in the arterial wall, initiating a cascade of foam cell formation, inflammatory cytokine release, smooth muscle cell proliferation, and ultimately atherosclerotic plaque development 2. This process leads directly to myocardial infarction, stroke, peripheral artery disease, and cardiac death 2.
Evidence Supporting ApoB as the Primary Driver
The evidence base is overwhelming across multiple study types:
Genetic studies: Familial hypercholesterolemia patients with mutations affecting ApoB clearance develop aggressive atherosclerosis in childhood when ApoB levels are markedly elevated 2
Mendelian randomization studies: Genetic variants that increase ApoB levels causally associate with increased ASCVD risk, independent of other factors 3, 4
Clinical outcomes data: Recent analysis of 389,529 individuals showed that when ApoB, non-HDL-C, and triglycerides were assessed together, only ApoB independently predicted myocardial infarction (adjusted HR 1.27 per 1 SD increase, P<0.001) 4
Plaque composition studies: Achieving ApoB <65 mg/dL associated with greater fibrous cap thickening (+44.6 vs +24.9 μm, P=0.007) and reduced thin-cap fibroatheroma prevalence (9.0% vs 40.0%, P<0.001) compared to higher ApoB levels 5
The Contrast with Apolipoprotein A1
In direct contrast, Apolipoprotein A1 (ApoA1) is the major protein of HDL and represents the "good" apolipoprotein 1. ApoA1 facilitates reverse cholesterol transport from peripheral tissues back to the liver. Low ApoA1 levels (<120 mg/dL in men, <140 mg/dL in women) correspond to low HDL-C and increased cardiovascular risk 1.
Clinical Implications
The 2024 Canadian guidelines and 2019 European guidelines now recognize that ApoB provides superior risk prediction compared to LDL-C or non-HDL-C alone 2, 6. This is particularly important in patients with:
- Hypertriglyceridemia (TG ≥2.3 mmol/L)
- Diabetes mellitus
- Metabolic syndrome
- Obesity (BMI ≥25 kg/m²)
- Very low LDL-C levels on treatment
In these populations, ApoB captures residual cardiovascular risk that LDL-C measurements miss 7, 6.
The key clinical pitfall: Patients can have "normal" LDL-C but elevated ApoB, indicating a high number of small, dense atherogenic particles that substantially increase cardiovascular risk 1, 8. This discordance is common and clinically significant—focusing solely on LDL-C in such patients leaves substantial residual risk unaddressed.